Reimmunization after blood or marrow stem cell transplantation

Bone Marrow Transplantation

Volumn 23, Issue 7, 1999, Pages 637-646

  Singhal, S ^a   Mehta, J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Allogeneic bone marrow transplantation; Autologous bone marrow transplantation; Hematopoietic stem cell transplantation; Immunization; Vaccination

Indexed keywords

BCG VACCINE; CHICKENPOX VACCINE; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; POLIOMYELITIS VACCINE; TYPHOID VACCINE; YELLOW FEVER VACCINE;

ADENOVIRUS; ADOPTIVE TRANSFER; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; DRUG CONTRAINDICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; MAJOR CLINICAL STUDY; PASSIVE IMMUNIZATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; VACCINATION;

EID: 0032891222     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701640     Document Type: Review

References (87)

1. Keusch GT, Bart KJ. Immunization principles and vaccine use. In: Isselbacher KJ, Braunwald E, Wilson JD et al (eds). Harrison's Principles of Internal Medicine, 13th edn. McGraw-Hill: New York, 1994, pp 498-511.
2. Lum LG, Munn NA, Schanfield MS, Storb R. The detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood 1986; 67: 582-587.
3. Lum LG, Seigneuret MC, Storb R. The transfer of antigen-specific homoral immunity from marrow donors to marrow recipients. J Clin Immunol 1986; 6: 389-396.
4. Wimperis JZ, Brenner MK, Prentice HG et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986; 1: 339-343.
5. Baumgartner C, Morell A, Hirt A et al. Humoral immune function in pediatric patients treated with autologous bone marrow transplantation for B cell non-Hodgkin's lymphoma. The influence of ex vivo marrow decontamination with anti-Y 29/55 monoclonal antibody and complement. Blood 1988; 71: 1211-1217.
6. Lum LG, Noges JE, Beatty P et al. Transfer of specific immunity in marrow recipients given HLA-mismatched, T cell-depleted, or HLA-identical marrow grafts. Bone Marrow Transplant 1988; 3: 399-406.
7. Lungman P, Fridell E, Lonqvist B et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989; 159: 610-615.
8. Ljungman P, Wiklund Hammarsten M, Duraj V et al. Response to tetanux toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 1990; 162: 496-500.
9. Rege K, Mehta J, Treleaven J et al. Fatal pneumococcal infections following allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14: 903-906.
10. Aucouturier P, Barra A, Intrator L et al. Long lasting IgG subclass and antibactreial polysaccharide antibody deficiency after allogeneic bone marrow transplantation. Blood 1987; 70: 779-785.
11. Lossos IS, Breuer R, Or R et al. Bacterial pneumonia in recipients of bone marrow transplantation. A five-year prospective study. Transplantation 1995; 60: 672-678.
12. Ljungman P, Cordonnier C, De Bock R et al. Immunisations after bone marrow transplantation: results of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1995; 15: 455-460.
13. Somani J, Larson RA. Reimmunization after allogeneic bone marrow transplantation. Am J Med 1995; 98: 389-398.
14. Henning KJ, White MH, Sepkowitz KA, Armstrong D. A national survey of immunization practices following allogeneic bone marrow transplantation. JAMA 1997; 277: 1148-11-51.
15. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood 1987; 69: 369-380.
16. Atkinson K. Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 1990; 5: 209-226.
17. Storek J, Ferrara S, Ku N et al. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant 1993; 12: 387-398.
18. Storek J, Witherspoon RP, Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant 1995; 16: 413-425.
19. + T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1997; 25: 600-606.
20. Roberts MM, To LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 469-475.
21. Ottinger HD, Beelen DW, Scheulen B et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775-2779.
22. Chan CY, Molrine DC, Antin JH et al. Antibody response to tetanus toxoid and Haemophilus influenzae type b conjugate vaccines following autologous peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant 1997; 20: 33-38.
23. Anonymous. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. Pediatrics 1997; 99: 479-488.
24. Anonymous. Recommended childhood immunization schedule - United States, 1998. Morb Mortal Wkly Rep 1998; 47: 8-12.
25. Parkkali T, Ruutu T, Stenvik M et al. Loss of protective immunity to polio, diphtheria and Haemophilus influenzae type b after allogeneic bone marrow transplantation. APMIS 1996; 104: 383-388.
26. Gratama JW, Verdonck LF, van der Linden JA et al. Cellular immunity to vaccinations and herpesvirus infections after bone marrow transplantation. Transplantation 1986; 41: 719-724.
27. Li Volti S, Mauro L, Di Gregorio F et al. Immune status and immune response to diphtheria-tetanus and polio vaccines in allogeneic bone marrow-transplanted thalassemic patients. Bone Marrow Transplant 1994; 14: 225-227.
28. Singhal S, Mehta J. Reimmunisation after transplantation. In: Barrett AJ, Treleaven J (eds). The Clinical Practice of Stem Cell Transplantation. Isis Medical Media: Oxford, UK 1998, pp 745-756.
29. Barra A, Cordonnier C, Preziosi MP et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 1992; 166: 1021-1028.
30. Guinan EC, Molrine DC, Antin JH et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 1994; 57: 677-684.
31. Parkkali T, Kayhty H, Ruutu T et al. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. Bone Marrow Transplant 1996; 18: 961-967.
32. Molrine DC, Guinnan EC, Antin JH et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood 1996; 87: 3012-3018.
33. Molrine DC, Guinana EC, Antin JH et al. Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation. Bone Marrow Transplant 1996; 17: 1149-1155.
34. Ilan Y, Nagler A, Adler R et al. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 1993; 18: 246-252.
35. Ilan Y, Nagler A, Adler R et al. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 1993; 104: 1818-1821.
36. Ilan Y, Nagler A, Shouval D et al. Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors. Clin Exp Immunol 1994; 97: 299-302.
37. Shouval D, Ilan Y. Immunization against hepatitis B through adoptive transfer of immunity. Intervirology 1995; 38: 41-46.
38. Brugger SA, Oesterreicher C, Hofmann H et al. Hepatitis B virus clearance by transplantation of bone marrow from hepatitis B immunised donor. Lancet 1997; 349: 996-997.
39. Lau GK, Liang R, Lee CK, Lim WL. Is vaccination of donor adequate for clearance of hepatitis B virus afer bone-marrow transplantation? Lancet 1997; 349: 1626-1627.
40. Caselitz M, Link H, Hein R et al. Hepatitis B associated liver failure following bone marrow transplantation. J Hepatol 1997; 27: 572-577.
41. Li Volti S, Di Gregorio F, Romeo MA et al. Immune status and the immune response to hepatitis B virus vaccine in thalassemic patients after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 157-160.
42. Nagler A, Ilan Y, Adler R et al. Successful immunization of autologous bone marrow transplantation recipients against hepatitis B virus by active vaccination. Bone Marrow Transplant 1995; 15: 475-478.
43. Potter MN, Foot AB, Oakhill A. Influenza A and the virus associated haemophagocytic syndrome: cluster of three cases in children with acute leukaemia. J Clin Pathol 1991; 44: 297-299.
44. Whimbey E, Elting LS, Couch RB et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994; 13: 437-440.
45. Engelhard D, Nagler A, Hardan I et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993; 11: 1-5.
46. Pauksen K, Duraj V, Ljungman P et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant 1992; 9: 427-432.
47. Ljungman P, Lewensohn-Fuchs I, Hammarstrom V et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood 1994; 84: 657-663.
48. de Quadros CA, Olive JM, Hersh BS et al. Measles elimination in the Americas. Evolving strategies. JAMA 1996; 275: 1311-1312.
49. Nakano T, Shimono Y, Sugiyama K et al. Clinical features of measles in immunocompromised children. Acta Paediatr Jpn 1996; 38: 212-217.
50. King SM, Saunders EF, Petric M, Gold R. Responses to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 633-636.
51. Pauksen K, Linde A, Ljungman P et al. Specific T and B cell immunity to measles after allogeneic and autologous bone marrow transplantation. Bone Marrow Transplant 1995; 16: 807-813.
52. Pauksen K, Linde A, Lonnerholm G et al. Influence of the specific T cell response on seroconversion after measles vaccination in autologous bone marrow transplant patients. Bone Marrow Transplant 1996; 18: 969-973.
53. Pauksen K, Sjolin J, Linde A et al. Th1 and Th2 cytokine responses after measles antigen stimulation in vitro in bone marrow transplant patients: response to measles vaccination. Bone Marrow Transplant 1997; 20: 317-323.
54. Witherspoon RP, Storb R, Ochs HD et al. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 1981; 58: 360-368.
55. Winston DJ, Ho WG, Schiffman G et al. Pneumococcal vaccination of recipients of bone marrow transplants. Arch Intern Med 1983; 143: 1735-1737.
56. Lortan JE, Vellodi J, Jurges ES, Hugh-Jones K. Class-and subsclass-specific pneumococcal antibody levels and response to immunization after bone marrow transplantation. Clin Exp Immunol 1992; 88: 512-519.
57. Avanzini MA, Carra AM, Maccario R et al. Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. J Clin Immunol 1995; 15: 137-144.
58. Hammarstrom V, Pauksen K, Azinge J et al. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction. Support Care Cancer 1993; 1: 195-199.
59. Storek J, Mendelman PM, Witherspoon RP et al. IgG response to pneumococcal polysaccharide-protein conjugate appears similar to IgG response to polysaccharide in bone marrow tranpslant recipients and healthy adults. Clin Infect Dis 1997; 25: 1253-1255.
60. de Quadros CA, Andrus JK, Olive JM, Carrasco P. Strategies for poliomyelitis eradication in developing countries. Public Health Rev 1993-94; 21: 65-81.
61. Anonymous. Progress towards global poliomyelitis eradication, 1985-1994. Morb Mortal Wkly Rep 1995; 44: 273-275, 281.
62. Engelhard D, Handsher R, Naparstek E et al. Immune response to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8: 295-300.
63. Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7: 89-93.
64. Parkkali T, Stenvik M, Ruutu T et al. Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT. Bone Marrow Transplant 1997; 20: 663-668.
65. Pauksen K, Hammarstrom V, Ljungman P et al. Immunity to poliovirus and immunization with inactivated poliovirus vaccine after autologous bone marrow transplantation. Clin Infect Dis 1994; 18: 547-552.
66. Sanders JE, Hawley J, Levy W et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996; 87: 3045-3052.
67. Singhal S, Powles R, Treleaven J et al. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility. Bone Marrow Transplant 1996; 18: 1049-1055.
68. Wimperis JZ, Brenner MK, Prentice HG et al. B cell development and regulation after T cell-depleted marrow transplantation. J Immunol 1987; 138: 2445-2450.
69. Parkkali T, Olander RM, Ruutu T et al. A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMT. Bone Marrow Transplant 1997; 19: 933-938.
70. Gerritsen EJ, van Tol MJ, van't Veer MB et al. Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation. Blood 1994; 84: 4374-4382.
71. Gerritsen EJ, van Tol MJ, Ballieux P et al. Search for the antigen-specificity of homogeneous IgG components (H-IgG) after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 17: 825-833.
72. Selby PJ, Powles RL, Easton D et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer 1989; 59: 434-438.
73. Sauerbrei A, Prager J, Hengst U et al. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 1997; 20: 381-383.
74. Redman RL, Nader S, Zerboni L et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Inject Dis 1997; 176: 578-585.
75. Salzman MB, Sharrar RG, Steinberg S, LaRussa P. Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother. J Pediatr 1997; 131: 10-12.
76. Obaro SK, Henderson DC, Monteil MA. Defective antibody-mediated opsonisation of S. pneumoniae in high risk patients detected by flow cytometry. Immunol Lett 1996 49: 83-89.
77. Shepherd DM, Noelle RJ. The lack of memory B cells in immune bone marrow. Transplantation 1991; 52: 97-100.
78. Singhal S, Powles R, Kulkarni S et al. Comparison of cell yields in a single-center, double-blind, randomized study of allogeneic marrow versus blood stem cell transplantation. Blood 1997; 90 (Suppl. 1): 592a.
79. Wimperis JZ, Gottlieb D, Duncombe AS et al. Requirements for the adoptive transfer of antibody responses to a priming antigen in man. J Immunol 1990; 144: 541-547.
80. Gottlieb DJ, Cryz SJ Jr, Furer E et al. Immunity against Pseudomonas aeruginosa adoptively transferred to bone marrow transplant recipients. Blood 1990; 76: 2470-2475.
81. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New Engl J Med 1995; 333: 1038-1044.
82. Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
83. Lutwick LI. Postexposure prophylaxis. Infect Dis Clin North Am 1996; 10: 899-915.
84. Sullivan KM, Kopecky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. New Engl J Med 1990; 323: 705-712.
85. Sullivan KM, Storek J, Kopecky KJ et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996; 2: 44-53.
86. Siber GR, Werner BG, Halsey NA et al. Interference of immune globulin with measles and rubella immunisation. J Pediatr 1993; 122: 204-211.
87. Dal-Re R, Gil A, Gonzalez A, Lasheras L. Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine? A comparative clinical trial in adults. J Clin Pharmacol 1995; 35: 420-425.